Antiplatelet Agents. Class Summary. These agents can be considered to help prevent future ischemic strokes. ... Anticoagulants, Hematologic. Class Summary. Once the diagnosis of VTE is made, therapeutic anticoagulation should be initiated ... Because data on the maternal and fetal safety of direct oral anticoagulants (DOACs) are scant, these agents are generally ...

Thrombolytic Agents. Class Summary. As advanced by the American College of Chest Physicians in the "Antithrombotic Therapy and ... Anticoagulants, Hematologic. Class Summary. Anticoagulant medications prevent further clot deposition. They allow the natural ... These agents dissolve recent clots promptly by activating a plasma proenzyme, plasminogen, to its active form, plasmin. Plasmin ... Because antibodies to streptokinase may develop and rt-PA has increasingly been used as the first-choice thrombolytic agent. ...

... Latest therapeutic developments in CAR T ...

Galbaud du Fort G (1988). "[Hematologic toxicity of antidepressive agents]" [Hematologic Toxicity of Antidepressive Agents]. ...

Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. ( 7.1) • Sorbitol: ... Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic ... which may increase the risk of hematologic toxicity. Frequent monitoring of hematologic toxicities is advised. ... Agents Antagonistic with Zidovudine Concomitant use of zidovudine with the following drugs should be avoided since an ...

Categories: Hematologic Agents Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted ...

An increased risk of bleeding may occur in patients taking a vitamin-K antagonist or an antiplatelet agent with selumetinib. ... Use caution or avoid in patients with hypersensitivity or hematologic reactions to previous thienopyridine use, including ... Monitor for bleeding and INR or PT in patients coadministered a vitamin-K antagonist or an antiplatelet agent with selumetinib. ... An increased risk of bleeding may occur in patients taking a vitamin-K antagonist or an antiplatelet agent with selumetinib. ...

... other investigator-initiated studies of bomedemstat either as monotherapy or in combination with other agents for hematologic ... the European Hematology Association and other important forums of hematologic research. A third Imago-sponsored global clinical ...

The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers. Investig. ... Shanmugam, M.K.; Warrier, S.; Kumar, A.P.; Sethi, G.; Arfuso, F. Potential Role of Natural Compounds as Anti-Angiogenic Agents ... It is a small molecule microtubule destabilizing agent that is synthetically derived. This drug is known to have the advantage ... BPR0C305, an orally active microtubule-disrupting anticancer agent. Anticancer Drugs 2013, 24, 1047-1057. [Google Scholar] [ ...

There is also a theoretical possibility that these agents increase the risk of hematologic malignancies, as thrombopoietin ... Antiplatelet agents have not been shown to alter the natural history of the disease. Milder forms of TTP may respond to ... Platelets do not aggregate to any agents except ristocetin. The more severe type I results from a complete absence of the GP ... Currently, these agents are recommended for ITP patients whose conditions are refractory to previous treatments, including ...

The authors appropriately point to the extraordinary promise of these agents in the treatment of hematologic malignancies. They ...

Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic ... Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic ... Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment FailureEpperla N, Costa L ... Current Hematologic Malignancy Reports 2017, 12: 257-267. PMID: 28233150, DOI: 10.1007/s11899-017-0369-y. ...

hematologic malignancy Clinical Research Trial Listings on CenterWatch ... I am looking forimmunosuppressive agents. I am looking forgrowth factor. ...

Our lab is interested in utilizing tumor-colonizing, bacterial-based agents as novel immunotherapy for solid and hematologic ... Design, perform and lead projects involving optimization of bacterial-based agents designed to elicit tumor-specific immunity, ...

Disinfectants (For Agents Used on Object). *Hematologic Agents. *Organic Anion Transporting Polypeptide 2B1 Inhibitors ... Citric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May ...

... are widely used chemotherapeutic agents for the treatment of solid tumors and hematologic malignancies. However, they ... 2020) Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19 Cancer 126:5069-5076 ... 2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients ... Figure 7 presents the results of the meta-analysis of eight studies on mortality in patients with hematologic neoplasms. The ...

Two microcatheter technique for embolization of arteriovenous fistula with liquid embolic agent. Neurointervention. 2014 Feb. 9 ... Anticoagulants, Hematologic. Class Summary. If angiographic evidence of thrombosis exists, anticoagulation with heparin may be ...

... a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic ... Tuspetinib APTIVATE Expansion Trial - In the APTIVATE Phase 1/2 clinical trial of tuspetinib, a once daily oral agent with a ... The Companys small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to ... The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239 ...

... has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic ... GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 ...

Do not use penicillamine with antineoplastic agents due to the increased risk of developing severe hematologic and renal ... Administer atezolizumab prior to chemotherapy or other antineoplastic agents when given on the same day.. Do not infuse through ... or within 24 hours after administration of antineoplastic agents. Penicillamine: (Major) ...

Antimicrob Agents Chemother. 2012;56:2108-13 . DOIPubMedGoogle Scholar ... First, patients with hematologic malignancies usually receive antimicrobial drugs recommended for the management of fever in ... In conclusion, in areas where KPC-Kp is endemic, progress in treating hematologic malignancies could be slowed by the emergence ... In our opinion, the high mortality rate related to KPC-Kp bloodstream infections in patients with hematologic malignancies ...

... and assessment of targeted therapeutic agents for hematologic malignancies. ... At Tufts, he held several positions, including leader of the Hematologic Malignancies Program and member of the graduate ...

... the observed progression-free survival in this study warrants further evaluation of this agent in hematologic cancers. ... Laboratory hematologic and biochemical abnormalities of any grade were reported in 63 patients (87.5%) and 71 patients (98.6 ... Dreyling M, Morschhauser F, Bron D. Preliminary results of a phase II study of single agent Bay 80-6946, a novel PI3K inhibitor ... Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. ...

Antimycobacterial Agents 0358 Antifungal Agents 0388 Antiviral Agents 0400 HEMATOLOGIC AGENTS 0408 Agents Used to Treat ... ANTICONVULSANT AGENT 35415 ANTIDEPRESSANT AGENT 35420 ANTIDIABETIC AGENT 35435 ANTIEPILEPSY AGENT 35445 ANTIFUNGAL AGENT 35450 ... Antiarrhythmic Agents 0503 Antianginal Agents 0504 Agents Used in Peripheral or Cerebral vascular Disorders 0505 Agents Used to ... Antidiarrheal Agents 0876 Laxatives 0877 Misc. Gastrointestinal Agents 9000 METABOLIC AND NUTRIENT AGENTS 0912 Agents Used to ...

Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response ... FDA Accepts Application for Mercks KEYTRUDA® (pembrolizumab) as Single Agent for Certain Patients With MSI-H/dMMR Advanced ... as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that ... KEYTRUDA as a Single Agent KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) ...

... as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors ... as a single agent and in combination with cytotoxic agents, in patients with refractory cancers. ... Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and ... Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors ...

Hematologic Agents - Preferred Concept UI. M0010043. Scope note. Drugs that act on blood and blood-forming organs and those ... Agents hématologiques Entry term(s):. Agents, Hematologic. Agents, Hematological. Hematological Agents. Tree number(s):. ...